Skip to main content

A major cancer drugmaker may need to buy its way out of a looming disaster

Buying Juno could help Celgene diversify its portfolio as its top-selling drug approaches patent expiration.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.